

Pharmabiotics Programme

14 - 15 MARCH, Paris

Conference Programme Sponsored by **LACTOSAN**



Key Notes



Live Biotherapeutics; Enhancing Health Through Modulating the Human Microbiome

Paul Cotter, Principal Investigator
APC Microbiome Institute



The Microbiome - What Pharma Needs, What Pharma Thinks?

Marie Linder, Global Program Head, Strategic Partnerships
Novartis



Pioneering Microbiome Innovations

David Berry, General Partner
Flagship Pioneering

Identifying Biomarkers



Targeting the gut microbiota in Diabetes – The potential role of probiotics

Angela Horvath, Post-Doctoral Researcher
Medical University of Graz



Emerging Biomarkers in Oncology Related to Microbiome Disruption. Where are we Now and Where do we Need to go?"

Jack Gilbert, Director, The Microbiome Center at UoC
John Slattery, Director of Research & Innovation, Aces Health Inc.




Biomarkers in Osteoarthritis: Where are we? Where are we going?

Yves Henrotin, Professor
University of Liège



Bioinformatic Challenges in Microbiome Analyses

Chaired by Bruno Pot, President, PRI



How Can You Trust your Analysis Results from Targeted Metagenomics Studies?

Ségolène Caboche, Bioinformatics Researcher
Université de Lille



The Challenges in Performing Metagenomic Studies to Understand the Role of Gut Microbiome in Diseases

Manimozhiyan Arumugam, Associate Professor
Novo Nordisk Foundation




Ultra-high Resolution Microbiomics

Pernille Myers, Bioinformatics Specialist
Clinical Microbiomics



Panel Discussion: How to Overcome the Difficulties Relating to the Inter-Analysis Variability


Chaired by Bruno Pot, President, PRI




Ségolène Caboche
Bioinformatics Researcher
Université de Lille



Manimozhiyan Arumugam
Associate Professor
Novo Nordisk Foundation



Stephanie Ferreira
Innovation Manager
GenoScreen



Sébastien Leuillet
Statistics & Bioinformatics Manager
Biofortis



Regulatory Affairs

Chaired by Colette Shortt, Global Regulatory Director, J&J



The PRI: An Innovative Approach in Absence of Clear Regulatory Framework at the EU Level

Magali Cordaillat-Simmons, Executive Scientist
Pharmabiotic Research Institute



Nagoya Protocol: Legal Framework and Practical Consequences

Katia Martin-Lentz, Partner
Keller and Heckman LLP

Interactive Session: Internationalisation of Regulatory Issues for Pharmabiotics: What Needs to be Done?




Magali Cordaillat-Simmons
Executive Scientist
PRI




Colette Shortt
Global Regulatory Director
Johnson & Johnson



Sin-Hyeog Im
Professor
IBS/POSTECH



Katia Merten-Lentz
Global Regulatory Director
Johnson & Johnson



Charlotte Hemmingsen
Senior Regulatory Manager
Chr. Hansen



Marie Lindner
Global Head, Strategic
Partnerships Team
Novartis



The Latest Science



How to develop Probiotics as Immune-modulatory Pharmabiotics?

Sin-Hyeog Im, Professor
IBS / POSTECH



The MyNewGut Project

Yolanda Sanz, Professor
IATA-CSIC

Pharmabiotics Young Investigator Awards

YIA finalist I | TB Selected



YIA finalist II | TB Selected

YIA finalist III | TB Selected

YIA Awards Ceremony & Cocktail Reception

Sponsored by PRI



Skin: A New Target for Microbiota Interventions

Chaired by Bernard Pietzold, CSO, S-Biomedic




Skin Microbiota: Interest and Management

Richard Martin, CEO
Mercurialis Biotech



Investigating and Understanding the Role of the Skin Microbiota in Skin Disorders

Holger Brüggemann, Associate Professor
AARHUS University



'Bugs as Drugs' for the Skin: Novel Microbiome-Based Strategies for Skin Diseases

Travis Witfil, Co-Founder & CSO
Azitra Inc., Yale University




Taxonomic Thunderclouds



Untangling the Evolutionary Development of the Genus Bifidobacterium by Comparative Genomics

Marco Ventura, Professor
University of Parma



Deciphering the Diversity of Genus Lactobacillus: A Taxonomic Tale

Giovanna Felis, Associate Professor
University of Verona




Innovation Showcase: Startup Pitch Slam

Chaired by Richard Ellis, Business Development, PRI



Developing Live Biotherapeutic Products



Personalized Pharmabiotics for Correction of Nosology and Individual Specific Microbiota and Immune Response

Nadya Boyko, Professor
Uzhorod National University



A Systematic Review with Meta-Analysis of a Pharmabiotic Composition for the Management of Ulcerative Colitis Remission in a Chinese Population


Thomas Tompkins, Research Director
Lallemand Health Solutions inc.

Featured Presentations




Standardizing Microbiomics – Removing Bias in Collection, Purification and Analyses

Sarah Hemmasi, Research Associate
Zymo Research




Biofortis Corporate Presentation

Sébastien Leuillet, Statistics & Bioinformatics Manager
Biofortis Mérieux NutriSciences



From Dysbiosis to Cancer: Microbiome Research in Oncology and its Impact for Health and Therapy

Adolf Heschl, Lecturer
Zoological Institute of the University of Graz



Therapeutic Potential of Probiotics for Mood: New Evidence from a Double-blind, Placebo Controlled Study

Marco Pane, Product Specialist
Probiotal

